Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
Form Type:
Zero Holdings:
Publication Time:
2014-12-19 10:15:50
Reporting Period:
Filing Date:
Accepted Time:
2014-12-19 10:15:50
SEC Url:
Form 4 Filing
Cik Name Symbol Sector (SIC) IRS No
890465 Nps Pharmaceuticals Inc NPSP Biological Products, (No Disgnostic Substances) (2836) 870439579
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1313793 R Rachel Selisker 550 Hills Drive
Bedminster NJ 07921
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2014-12-17 1,208 $4.24 11,108 No 4 M Direct
Common Stock Disposition 2014-12-17 3,708 $34.59 7,400 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Options (right to buy) Disposition 2014-12-17 1,208 $0.00 1,208 $4.24
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2019-09-23 No 4 M Direct
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.51 to $35.00, inclusive. The reporting person undertakes to provide to NPS Pharmaceuticals, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4.
  3. On September 23, 2009, the reporting person received a grant of 36,000 stock options under the Issuer's 2005 Omnibus Incentive Plan. These options vested and became exercisable based on the following vesting schedule: 25% on each of the first anniversary of the date of grant and 6.25% every three months thereafter.. As of the date of this filing, all 36,000 stock options have vested.